Blog

The Alliance’s blog offers a personal, inside look at our activities and perspectives on a range of timely issues. We encourage your feedback.

Two New Clinical Studies Request Volunteers

Author: Noel Lloyd

Date: August 3rd, 2015

We are sharing the following information about two new clinical studies.


Don’t Just Act Out, Act to Increase Representation in Clinical Trials

Author: Cynthia Bens

Date: August 29th, 2014

Vice President of Public Policy Cynthia Bens talks about clinical trials.


Participate in an Alzheimer's Disease Clinical Trial

Author: Noel Lloyd

Date: November 12th, 2015

Participating in Alzheimer's disease clinical trials is a valuable way you and your loved ones can personally impact this disease.


Cynthia Bens Comments from MDUFA and PDUFA Meetings

Author: Noel Lloyd

Date: July 16th, 2015

Alliance Vice President of Public Policy Cynthia Bens took part in two important meetings at the U.S. Food and Drug Administration this week.


Alliance's Bens to Participate in Symposium on Frailty

Author: Noel Lloyd

Date: March 29th, 2016

On April 7, the Alliance's Vice President of Public Policy Cynthia Bens will participate in a symposium titled "Frailty as a Baseline Stratification Parameter and Potential Therapeutic Target" at the 28th Annual EuroMeeting in Hamburg, Germany.


Alliance Comments on the FDA's Commitment Letter for PDUFA VI

Author: Noel Lloyd

Date: August 30th, 2016

In response to a call from the U.S. Food and Drug Administration (FDA) for feedback on its proposed Commitment Letter for the sixth reauthorization of the Prescription Drug User Fee Act (PDUFA), the Alliance for Aging Research submitted comments to the FDA for consideration.


Alliance's Bens Will Testify on MDUFA and PDUFA Reauthorization

Author: Breanna Bishop

Date: April 3rd, 2017

On April 4, the Alliance for Aging Research’s Vice President of Public Policy Cynthia Bens will testify before the U.S. Senate Committee on Health, Education, Labor and Pensions about the reauthorization of the Prescription Drug User Fee Act and the Medical Device User Fee Act. You can watch the hearing here.


Update on Patient-Focused Drug Development Meeting on Sarcopenia

Author: Noel Lloyd

Date: April 20th, 2017

On April 6, the U.S. Food and Drug Administration held a public meeting on Patient-Focused Drug Development (PFDD) for sarcopenia. The focus of the meeting was to obtain patient perspectives on “symptoms and the daily impacts of their condition, current approaches to treatment, and decision factors taken into account when selecting a treatment.”

Living Longer & Loving It

Sign up for our electronic newsletter Living Longer & Loving It